Home/Filings/4/0001062993-22-010574
4//SEC Filing

Pivotal bioVenture Partners Fund I, L.P. 4

Accession 0001062993-22-010574

CIK 0001693011other

Filed

Apr 19, 8:00 PM ET

Accepted

Apr 20, 6:22 PM ET

Size

9.9 KB

Accession

0001062993-22-010574

Insider Transaction Report

Form 4
Period: 2022-04-19
Transactions
  • Purchase

    Common Stock

    2022-04-19$3.69/sh+1,070,000$3,948,3002,661,154 total(indirect: See footnotes)
Transactions
  • Purchase

    Common Stock

    2022-04-19$3.69/sh+1,070,000$3,948,3002,661,154 total(indirect: See footnotes)
Transactions
  • Purchase

    Common Stock

    2022-04-19$3.69/sh+1,070,000$3,948,3002,661,154 total(indirect: See footnotes)
Footnotes (2)
  • [F1]The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL").
  • [F2]The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Mr. Kin Ho Kwok, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

Issuer

Inozyme Pharma, Inc.

CIK 0001693011

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001695076

Filing Metadata

Form type
4
Filed
Apr 19, 8:00 PM ET
Accepted
Apr 20, 6:22 PM ET
Size
9.9 KB